Clinical Trial Update: Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating intraperitoneal paclitaxel for primary malignant peritoneal mesothelioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peritoneal Malignant Mesothelioma

Drugs mentioned

• Paclitaxel (intraperitoneal) (paclitaxel)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Peritoneal Malignant Mesothelioma | Phase 1, Phase 2 | Status: COMPLETED